Additional positive Phase III results for sotagliflozin

15 August 2017

US biotech firm Lexicon Pharmaceuticals (Nasdaq: LXRX) today released additional positive data from the pivotal Phase III inTandem2 study of sotagliflozin, an investigational dual SGLT1 and SGLT2 inhibitor.

Lexicon’s share edged up 0.8% to $15.01 in pre-market trading, but were down 3.2% at $14.41 mid-mornig .

It was previously announced that both doses of sotagliflozin achieved the primary endpoint of the inTandem2 study, showing statistically-significant reductions in A1C at 24 weeks in adult patients with type 1 diabetes on a background of optimized insulin. The new data showed that the A1C benefit was sustained over 52 weeks as well as achievement of all secondary endpoints for both sotagliflozin doses. These results of the inTandem2 study, conducted primarily in Europe, replicated results previously reported from Lexicon's Phase III inTandem1 study of sotagliflozin in type 1 diabetes patients, conducted in North America.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK